

**Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029**

Market Report | 2024-10-22 | 319 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029 from USD 7.38 billion in 2024, at a CAGR of 22.5% during the forecast period of 2024 to 2029. The growth of the oral proteins and peptides market has been significantly driven by its increasing demand of oral peptides for the treatment of chronic diseases such as diabetes and CNS disorders, increasing R&D investment by key players for the development and launch of innovative oral peptides and continuous advancements in drug delivery technologies. However, high development cost and the hurdles in formulation and stability are restraining market growth.

"The semaglutide molecule segment accounted for the largest share by molecule in 2023."

In 2023, the semaglutide segment accounted for the largest share by molecule in the global oral proteins and peptides market. Semaglutide is an analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood sugar levels and appetite. It is used for the management of type-2 diabetes and obesity. Semaglutide works by enhancing insulin secretion in response to elevated blood glucose, reducing glucagon release (which raises blood sugar), and promoting a feeling of fullness after eating, which can help reduce food intake. Oral semaglutide (Rybelsus) is the first oral glucagon-like peptide 1 (GLP-1) receptor agonist product approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely used and recommended for the management of type 2 diabetes.

"The US has continued to dominate the oral proteins and peptides market during the forecast period of 2024-2029."

The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals' importance, and the necessity of safe

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of oral proteins and peptides in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), Pfizer Inc. (US)

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

-□By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of key Companies Profiled in the Report:

Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio LTD. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)

Research Coverage:

This research report categorizes the oral proteins and peptides market by molecule (Trofinetide, Semaglutide, Linaclotide, Voclosporin, Plecanatide, Calcitonin, and Others), by Drug Class (Analog of Glycine-Proline-Glutamate (GPE), Glucagon Like Peptide-1 (GLP-1) Receptor Agonist, Guanylate Cyclase-C Agonists, Calcineurin-Inhibitor Immunosuppressant, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist, and Others), by Therapeutic Area (Genetic Disorder, Diabetes, Nephrology, Gastroenterology, CNS Disorders, Obesity & Overweight, and Others) by Formulation (Tablet, Capsules, and Oral Solution), by End User (Home Care Settings, Long-Term Care Facilities, Hospitals & Specialty Clinics) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the oral proteins and peptides market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

-□Analysis of key drivers (Rising Prevalence of Chronic Diseases such as diabetes, gastroenterology diseases and kidney diseases, Advancements in Drug Delivery Technologies, Patient Preference and Compliance for oral route of drug administration, Increasing adoption of inorganic growth strategies such as collaboration and agreement), restraints (High cost is associated with drug development, Contraindication of oral proteins and peptides, Stringent regulatory approval process), opportunities (Robust clinical trial pipeline for oral proteins and peptides drug, Growing demand for non-invasive and patient-friendly treatment options), and Challenges (Hurdles in formulation and stability, Availability of alternative therapies) influencing the growth of the market).

-□Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the oral proteins and peptides market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market

-□Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.

**Table of Contents:**

- 1 INTRODUCTION 32
  - 1.1 STUDY OBJECTIVES 32
  - 1.2 MARKET DEFINITION 32
  - 1.3 MARKET SCOPE 33
    - 1.3.1 MARKETS COVERED 33
    - 1.3.2 INCLUSIONS & EXCLUSIONS 34
    - 1.3.3 YEARS CONSIDERED 34
    - 1.3.4 CURRENCY CONSIDERED 35
  - 1.4 STAKEHOLDERS 35
- 2 RESEARCH METHODOLOGY 36
  - 2.1 RESEARCH DATA 36
    - 2.1.1 SECONDARY DATA 37
    - 2.1.2 PRIMARY DATA 37
  - 2.2 MARKET SIZE ESTIMATION 39
    - 2.2.1 INSIGHTS FROM PRIMARIES 41
    - 2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL 41
  - 2.3 MARKET GROWTH FORECAST 42
  - 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 44
  - 2.5 STUDY ASSUMPTIONS 45
  - 2.6 RESEARCH LIMITATIONS 45
  - 2.7 RISK ANALYSIS 45
- 3 EXECUTIVE SUMMARY 46
- 4 PREMIUM INSIGHTS 51
  - 4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW 51
  - 4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2023) 52
  - 4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2023 52
  - 4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2024 VS. 2029 53
  - 4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
- 5 MARKET OVERVIEW 54
  - 5.1 INTRODUCTION 54
  - 5.2 MARKET DYNAMICS 54
    - 5.2.1 DRIVERS 55
      - 5.2.1.1 Increasing burden of chronic diseases 55
      - 5.2.1.2 Advancements in drug delivery technologies 56
      - 5.2.1.3 Higher patient compliance and preference for oral route 56
      - 5.2.1.4 Expanding therapeutic applications of oral proteins & peptides 57
    - 5.2.2 RESTRAINTS 57
      - 5.2.2.1 High cost of drug development 57
      - 5.2.2.2 Contraindication of oral proteins & peptides 57
      - 5.2.2.3 Stringent regulatory approval process 58
    - 5.2.3 OPPORTUNITIES 58
      - 5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides 58
      - 5.2.3.2 Growing demand for personalized medicine 59

5.2.4	CHALLENGES	59
5.2.4.1	Hurdles in formulation and stability	59
5.2.4.2	Availability of alternative therapies	60
5.3	ECOSYSTEM ANALYSIS	61
5.3.1	ROLE OF RAW MATERIAL VENDORS	61
5.3.2	ROLE OF PRODUCT PROVIDERS	62
5.3.3	ROLE OF END USERS	62
5.3.4	ROLE OF REGULATORY AUTHORITIES	62
5.4	VALUE CHAIN ANALYSIS	63
5.5	SUPPLY CHAIN ANALYSIS	65
5.6	PORTER'S FIVE FORCES ANALYSIS	66
5.6.1	THREAT OF NEW ENTRANTS	67
5.6.2	THREAT OF SUBSTITUTES	67
5.6.3	BARGAINING POWER OF SUPPLIERS	68
5.6.4	BARGAINING POWER OF BUYERS	68
5.6.5	INTENSITY OF COMPETITIVE RIVALRY	68
5.7	KEY STAKEHOLDERS & BUYING CRITERIA	68
5.7.1	KEY STAKEHOLDERS	68
5.7.2	BUYING CRITERIA	69
5.8	PRICING ANALYSIS	71
5.8.1	PRICING ANALYSIS OF ORAL PROTEIN & PEPTIDE PRODUCTS	71
5.8.2	PRICING ANALYSIS OF TOP ORAL PROTEINS & PEPTIDES, BY COUNTRY AND REGION	72
5.9	REGULATORY LANDSCAPE	73
5.9.1	REGULATORY SCENARIO	73
5.9.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	74
5.10	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	77
5.11	TECHNOLOGY ANALYSIS	77
5.11.1	KEY TECHNOLOGIES	77
5.11.1.1	Transient permeation enhancer	77
5.11.1.2	Gastrointestinal permeation enhancement technology	78
5.11.1.3	Oral sCT (OSTORA) technology	78
5.11.2	COMPLEMENTARY TECHNOLOGIES	78
5.11.2.1	Peptelligence	78
5.11.2.2	ThioMatrix	78
5.11.2.3	Transferrin-based recombinant fusion protein	79
5.11.3	ADJACENT TECHNOLOGIES	79
5.11.3.1	Oramed and Orasome	79
5.11.3.2	Q-sphera	79
5.11.3.3	Nanoinclusion	79
5.11.3.4	Oleotec and Soctec	80
5.12	PIPELINE ANALYSIS	80
5.13	PATENT ANALYSIS	81
5.13.1	METHODOLOGY	81
5.13.2	INNOVATION AND PATENT APPLICATIONS	81
5.13.3	TOP APPLICANTS	81
5.14	KEY CONFERENCES & EVENTS, 2024-2025	83
5.15	INVESTMENT & FUNDING SCENARIO	84

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

5.16	IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET	85
6	ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE	87
6.1	INTRODUCTION	88
6.2	SEMAGLUTIDE	88
6.2.1	INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH	88
6.3	CALCITONIN	91
6.3.1	NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION	91
6.4	LINACLOTIDE	94
6.4.1	RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH	94
6.5	TROFINETIDE	96
6.5.1	FDA APPROVAL TO SUPPORT GROWTH	96
6.6	VOCLOSPORIN	99
6.6.1	INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION	99
6.7	PLECANATIDE	101
6.7.1	INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH	101
6.8	OTHER MOLECULES	103
7	ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS	107
7.1	INTRODUCTION	108
7.2	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS	108
7.2.1	INCREASING ADOPTION TO SUPPORT GROWTH	108
7.3	CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS	111
7.3.1	INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION	111
?		
7.4	GUANYLATE CYCLASE-C AGONISTS	114
7.4.1	RISING PREVALENCE OF IBS, CIC TO DRIVE MARKET	114
7.5	GLYCINE-PROLINE-GLUTAMATE	117
7.5.1	FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH	117
7.6	CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS	119
7.6.1	INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH	119
7.7	OTHER DRUG CLASSES	121
8	ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA	125
8.1	INTRODUCTION	126
8.2	DIABETES	126
8.2.1	HIGH EFFICACY TO SUPPORT END-USER ADOPTION	126
8.3	CNS DISORDERS	130
8.3.1	GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET	130
8.4	GASTROENTEROLOGY	133
8.4.1	RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH	133
8.5	GENETIC DISORDERS	136
8.5.1	GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH	136
8.6	NEPHROLOGY	139
8.6.1	RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET	139
8.7	OBESITY & OVERWEIGHT	141
8.7.1	RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH	141
8.8	OTHER THERAPEUTIC AREAS	143
9	ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION	146
9.1	INTRODUCTION	147

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

9.2	TABLETS	147
9.2.1	HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH	147
9.3	CAPSULES	150
9.3.1	RIISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET	150
9.4	ORAL SOLUTIONS	153
9.4.1	GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH	153
10	ORAL PROTEINS & PEPTIDES MARKET, BY END USER	156
10.1	INTRODUCTION	157
10.2	HOME CARE SETTINGS	157
10.2.1	RIISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH	157
	?	
10.3	LONG-TERM CARE FACILITIES	160
10.3.1	RIISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH	160
10.4	HOSPITALS & SPECIALTY CLINICS	163
10.4.1	ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH	163
11	ORAL PROTEINS & PEPTIDES MARKET, BY REGION	167
11.1	INTRODUCTION	168
11.2	NORTH AMERICA	168
11.2.1	NORTH AMERICA: MACROECONOMIC OUTLOOK	169
11.2.2	US	173
11.2.2.1	US to hold large share of North American and global markets	173
11.2.3	CANADA	175
11.2.3.1	Increasing prevalence of obesity and heart failure to support market growth	175
11.3	EUROPE	177
11.3.1	EUROPE: MACROECONOMIC OUTLOOK	178
11.3.2	GERMANY	182
11.3.2.1	Germany to hold largest share of European market	182
11.3.3	UK	185
11.3.3.1	Strong focus on advancement of life sciences to support market growth	185
11.3.4	FRANCE	187
11.3.4.1	Growing prevalence of diabetes and government initiatives to boost market growth	187
11.3.5	ITALY	190
11.3.5.1	Presence of major pharmaceutical and biotechnology companies to drive market	190
11.3.6	SPAIN	192
11.3.6.1	Initiatives associated with GLP-1 drugs to drive market	192
11.3.7	NETHERLANDS	195
11.3.7.1	Rising awareness and focus on pharmaceutical R&D to support market growth	195
11.3.8	REST OF EUROPE	197
11.4	ASIA PACIFIC	199
11.4.1	ASIA PACIFIC: MACROECONOMIC OUTLOOK	200
11.4.2	CHINA	203
11.4.2.1	Increasing R&D expenditure to drive market	203
11.4.3	JAPAN	206
11.4.3.1	Increasing prevalence of diabetes to drive market	206
11.4.4	INDIA	208
11.4.4.1	Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth	208
11.4.5	AUSTRALIA	211

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.4.5.1	Rising access to GLP-1 drugs and government support to drive market	211
11.4.6	SOUTH KOREA	213
11.4.6.1	Growing focus on development of innovative treatment solutions to propel market growth	213
11.4.7	REST OF ASIA PACIFIC	216
11.5	LATIN AMERICA	218
11.5.1	LATIN AMERICA: MACROECONOMIC OUTLOOK	218
11.5.2	BRAZIL	221
11.5.2.1	Brazil to hold largest market share in Latin America	221
11.5.3	MEXICO	224
11.5.3.1	Growing diabetes and obesity cases to support market growth	224
11.5.4	REST OF LATIN AMERICA	226
11.6	MIDDLE EAST	229
11.6.1	MIDDLE EAST: MACROECONOMIC OUTLOOK	229
11.6.2	GCC COUNTRIES	232
11.6.2.1	Saudi Arabia	235
11.6.2.1.1	Growing availability of GLP-1 drugs to support market growth	235
11.6.2.2	UAE	237
11.6.2.2.1	Growing regulatory approvals for GLP-1 drugs to propel market	237
11.6.2.3	Rest of GCC countries	240
11.6.3	REST OF MIDDLE EAST	242
11.7	AFRICA	244
11.7.1	LARGE AND GROWING PATIENT POPULATION, FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET	244
11.7.2	AFRICA: MACROECONOMIC OUTLOOK	244
12	COMPETITIVE LANDSCAPE	248
12.1	OVERVIEW	248
12.2	KEY STRATEGIES/RIGHT TO WIN	248
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES	249
12.3	REVENUE SHARE ANALYSIS	250
12.4	MARKET SHARE ANALYSIS	250
12.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	252
12.5.1	STARS	252
12.5.2	EMERGING LEADERS	252
12.5.3	PERVASIVE PLAYERS	253
12.5.4	PARTICIPANTS	253
?		
12.6	COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023	254
12.6.1	STARS	254
12.6.2	EMERGING LEADERS	254
12.6.3	PERVASIVE PLAYERS	254
12.6.4	PARTICIPANTS	254
12.6.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	256
12.6.5.1	Company Footprint	256
12.6.5.2	Molecule footprint	258
12.6.5.3	Formulation footprint	258
12.6.5.4	Therapeutic area footprint	259
12.6.5.5	Region footprint	260
12.7	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	262

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.7.1	PROGRESSIVE COMPANIES	262
12.7.2	RESPONSIVE COMPANIES	262
12.7.3	DYNAMIC COMPANIES	262
12.7.4	STARTING BLOCKS	262
12.7.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	264
12.7.5.1	Detailed list of key startups/SMEs	264
12.7.5.2	Competitive benchmarking of key startups/SMEs	265
12.8	VALUATION & FINANCIAL METRICS	266
12.8.1	FINANCIAL METRICS	266
12.8.2	COMPANY VALUATION	266
12.9	BRAND/PRODUCT COMPARISON	267
12.10	COMPETITIVE SCENARIO	268
12.10.1	PRODUCT APPROVALS	268
12.10.2	DEALS	269
12.10.3	EXPANSIONS	270
12.10.4	OTHER DEVELOPMENTS	270
13	COMPANY PROFILES	272
13.1	INTRODUCTION	272
13.2	KEY PLAYERS	272
13.2.1	NOVO NORDISK A/S	272
13.2.1.1	Business overview	272
13.2.1.2	Products offered	273
13.2.1.3	Recent developments	274
13.2.1.3.1	Product launches & approvals	274
13.2.1.3.2	Expansions	274
13.2.1.3.3	Other developments	275
13.2.1.4	MnM view	275
13.2.1.4.1	Right to win	275
13.2.1.4.2	Strategic choices	275
13.2.1.4.3	Weaknesses & competitive threats	275
13.2.2	ABBVIE INC.	276
13.2.2.1	Business overview	276
13.2.2.2	Products offered	277
13.2.2.3	Recent developments	278
13.2.2.3.1	Product approvals	278
13.2.2.4	MnM view	278
13.2.2.4.1	Right to win	278
13.2.2.4.2	Strategic choices	278
13.2.2.4.3	Weaknesses & competitive threats	279
13.2.3	PFIZER INC.	280
13.2.3.1	Business overview	280
13.2.3.2	Product pipeline	281
13.2.3.3	Recent developments	282
13.2.3.3.1	Product approvals	282
13.2.3.3.2	Deals	282
13.2.3.3.3	Other developments	283
13.2.3.4	MnM view	283



13.2.3.4.1	Right to win	283
13.2.3.4.2	Strategic choices	283
13.2.3.4.3	Weaknesses & competitive threats	283
13.2.4	BAUSCH HEALTH COMPANIES INC.	284
13.2.4.1	Business overview	284
13.2.4.2	Products offered	285
13.2.4.3	Recent developments	286
13.2.4.3.1	Product approvals	286
13.2.5	CHIESI FARMACEUTICI S.P.A.	287
13.2.5.1	Business overview	287
13.2.5.2	Products offered	288
13.2.5.3	Recent developments	288
13.2.5.3.1	Deals	288
13.2.6	ACADIA PHARMACEUTICALS INC.	289
13.2.6.1	Business overview	289
13.2.6.2	Products offered	290
13.2.6.3	Recent developments	290
13.2.6.3.1	Product approvals	290
13.2.7	AURINIA PHARMACEUTICALS INC.	291
13.2.7.1	Business overview	291
13.2.7.2	Products offered	292
13.2.7.3	Recent developments	292
13.2.7.3.1	Product approvals	292
?		
13.2.8	MERCK & CO., INC.	293
13.2.8.1	Business overview	293
13.2.8.2	Product pipeline	294
13.2.8.3	Recent developments	295
13.2.8.3.1	Other developments	295
13.2.9	JOHNSON & JOHNSON SERVICES, INC.	296
13.2.9.1	Business overview	296
13.2.9.2	Product pipeline	297
13.2.9.3	Recent developments	298
13.2.9.3.1	Other developments	298
13.2.10	SWK HOLDINGS	299
13.2.10.1	Business overview	299
13.2.10.2	Product pipeline	300
13.2.10.3	Recent developments	300
13.2.10.3.1	Other developments	300
13.2.11	R-PHARM JSC	301
13.2.11.1	Business overview	301
13.2.11.2	Products in pipeline	301
13.2.12	ENTERA BIO LTD.	302
13.2.12.1	Business overview	302
13.2.12.2	Product pipeline	302
13.2.12.3	Recent developments	303
13.2.12.3.1	Deals	303

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

13.2.12.3.2	Other developments	303
13.2.13	PROXIMA CONCEPTS	304
13.2.13.1	Business overview	304
13.2.13.2	Products in pipeline	304
13.3	OTHER PLAYERS	305
13.3.1	ASTRAZENECA PLC	305
13.3.2	REGOR THERAPEUTICS GROUP	305
13.3.3	TERNIS PHARMACEUTICALS, INC.	306
13.3.4	STRUCTURE THERAPEUTICS	306
13.3.5	VIKING THERAPEUTICS	307
13.3.6	PROTAGONIST THERAPEUTICS INC.	307
13.3.7	RANI THERAPEUTICS	308
13.3.8	CARMOT THERAPEUTICS, INC.	308
13.3.9	ZEALAND PHARMA	309
13.3.10	SCIWIND BIOSCIENCES CO., LTD.	309
13.3.11	JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.	310
?		
14	APPENDIX	311
14.1	DISCUSSION GUIDE	311
14.2	KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL	315
14.3	CUSTOMIZATION OPTIONS	317
14.4	RELATED REPORTS	317
14.5	AUTHOR DETAILS	318

**Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin),  
Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes,  
Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast  
to 2029**

Market Report | 2024-10-22 | 319 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code\*

Country\*

Date

Signature